Entecavir Tablets IP 0.5 Mg – Entegic 0.5 Tablets

Entecavir Tablets IP 0.5 Mg – Potent First-Line Therapy for Chronic Hepatitis B.

Entegic 0.5 Tablets: The Composition of Entecavir Tablets IP 0.5 Mg is a guanosine nucleoside analogue with potent antiviral activity against HBV. It reduces HBV DNA levels significantly and improves liver histology. With a high genetic barrier and sustained efficacy, Entecavir remains a gold standard in chronic hepatitis B management.

Recommended By Specialists:
Infectious Disease Specialists: It is preferred to treat the disease associated with HBV that is linked with immunocompromised states
Hepatologists: It is preferred that the disease associated with primary specialists be treated for liver diseases, including chronic Hepatitis B.
Gastroenterologists – It is preferred to treat the disease associated with managing viral hepatitis and liver-related complications.

Key Benefits of Entecavir Tablets IP 0.5 Mg – Entegic 0.5 Tablets:
High Barrier to Resistance – Strong viral suppression with low mutation rates; ideal for long-term HBV therapy.
Superior Antiviral Potency: It inhibits all three activities of HBV polymerase: priming, reverse transcription, and DNA synthesis.
Excellent Safety Profile – Minimal renal and bone toxicity with once-daily dosing for better patient adherence.

INDICATIONS:
Chronic Hepatitis B Infection
Compensated Liver Disease due to HBV
Post-Transplant HBV Prophylaxis